Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Open-label, Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Subjects With High-risk Biochemical Recurrence of Nonmetastatic Castration-sensitive Prostate Cancer After Definitive Therapy

NCT06555796 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT06555796
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06555796 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Open-label, Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Subjects With High-risk Biochemical Recurrence of Nonmetastatic Castration-sensitive Prostate Cancer After Definitive Therapy
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 23, 2024
Completion date
May 7, 2029
Enrollment
50 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

high risk biochemical recurrence of non-metastatic castration-sensitive prostate cancer, high-risk biochemical recurrence, non-metastatic castration-sensitive prostate cancer, prostate cancer